Sign inJoin waitlistJoin the waitlist

Caron Jacobsen

Medical Director, Immune Effector Cell Therapy Program · Mass General Brigham

Credentials: · · · ·

History

Immune Effector Cell Therapy Program · Mass General Brigham
Present
Mass General Brigham
Present

Hematology and Medical Oncology
Dana-Farber Cancer Institute
2007–2010
New York Presbyterian Hospital
2004–2007
Columbia Univ Coll of Phys & Surgeons
2000–2004

Research

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
New England Journal of Medicine · 2017 · 4,914 citations
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
The Lancet Oncology · 2019 · 1,921 citations
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
New England Journal of Medicine · 2020 · 1,512 citations

Philippe Armand
49 papers
David Fisher
34 papers
Ann LaCasce
32 papers
Eric Jacobsen
29 papers
FL
Frederick Locke
27 papers
Jennifer Crombie
26 papers · 2 as a fellow
Matthew Davids
25 papers
Austin Kim
24 papers
David Miklos
24 papers
Reid Merryman
24 papers · 5 as a fellow
Jennifer Brown
23 papers
Sattva Neelapu
23 papers

Clinical trials

Axi-cel in CNS Lymphoma
Principal investigator · Active not recruiting · Phase 1
Dana-Farber Cancer Institute
2020–2038
Rituximab + Immunotherapy in Follicular Lymphoma
Principal investigator · Terminated · Phase 1
Dana-Farber Cancer Institute
2018–2023
Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL
Principal investigator · Terminated · Phase 2
National Cancer Institute (NCI)
2016–2021
A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
2014–2021